Dynamic CT Myocardial Perfusion Imaging

NCT ID: NCT02593838

Last Updated: 2021-10-06

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-30
• Study Completion Date: 2021-09-28

Brief Summary

This study aims at evaluating the feasibility of CT myocardial perfusion imaging in daily clinical practice and compare it to SPECT perfusion imaging in order to assess sensitivity and specifity of CT myocardial perfusion imaging compared to SPECT.

Detailed Description

If after the clinically indicated CCTA a myocardial perfusion examination is indicated, first a single ultra low dose CT scan will be performed to look for late enhancement of potentially scarred myocardium. Together with the contrast agent co-injection of the clinically indicated tracer 99mTc-Tetrofosmin will be performed for later scintigraphic perfusion evaluation. After stress perfusion imaging CT rest perfusion imaging will be performed in a similar fashion. After acquisition of CT rest perfusion images scintigraphic stress and rest image acquisition will be performed as in daily clinical routine with an additional administration of 99mTc-Tetrofosmin resting dose if necessary.

CT stress and rest perfusion will be compared to the clinically indicated and well established SPECT examination.

Conditions

Coronary Artery Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

CTP and SPECT-MPI

Every patient enrolled will undergo CT-MPI and SPECT-MPI. The latter is clinically indicated,.

Group Type: OTHER

CT-MPI and SPECT-MPI

Intervention Type: OTHER

All patients undergo CT-MPI plus SPECT-MPI

Interventions

CT-MPI and SPECT-MPI

All patients undergo CT-MPI plus SPECT-MPI

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Referral for cardiac hybrid imaging with CCTA and SPECT
• Male and Female subjects 18 years of age or older,
• Written informed consent by the participant after information about the project

Exclusion Criteria

• Contraindications for CCTA (including renal failure with a GFR <60ml/min/1.73m2, allergies to ionidated constrast agents)
• Inability to follow the examination procedure due to language barriers, mental disease, dementia etc.
• Pregnancy or breast feeding
• Known allergies to iodinated contrast agent (Visipaque ®), 99mTc-Tetrofosmin (Myoview ®), betablockers (Beloc i.v. ®) or nitrates (Isoket -Spray®)
• Hypersensitivity to adenosine
• Asthma bronchiale

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Zurich

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ronny R Buechel, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Zurich, Department of Nuclear Medicine

Locations

Department of Nuclear Medicine, University Hospital Zurich

Zurich, , Switzerland

Countries

Switzerland

Other Identifiers

USZ-2015-0393

Identifier Type: -

Identifier Source: org_study_id